BERGENBIO ASA: Board approval of 2022 Annual Financial Statement and Annual Report 2022

Bergen, Norway – 28 April 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, announces that the Board of Directors today approved the 2022 Annual Financial Statements prepared in accordance with International Financial Reporting Standards (IFRS).


The Annual Report for 2022 in pdf and European Single Electronic Format (ESEF) are attached to this release and are also available on BerGenBio ASA's website




For BerGenBio: Martin Olin CEO, BerGenBio ASA  


Rune Skeie, CFO, BerGenBio ASA



About BerGenBio ASA


BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate bemcentinib a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and severe respiratory infections.  

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit

Forward looking statements

This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.